The Latest Breaking News from Omicron

The next generation of COVID-19 booster shots — tailored specifically to combat the highly infectious family of omicron subvariants — could roll out early next month.

UK hit by fifth wave of infections earlier this summer driven by new Omicron variants

Around one in five vaccinated Britons with Omicron or Delta strain experienced diarrhoea as a symptom

They're expected to become available right after Labor Day.

Fainting and fatigue may signal onset of variant, experts say

LOS ANGELES — Experts are warning that employees might be showing up to work while sick with COVID-19, with symptoms so mild even health care workers are being fooled.

UK hit by fifth wave of infections earlier this summer driven by new Omicron variants

The latest COVID-19 surge is waning — but long COVID will be the next public health crisis

Everything you need to know on how common reinfections are

Fainting and fatigue may signal onset of variant, experts say

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…